Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma.
Yang S, Yang X, Hou Z, Zhu L, Yao Z, Zhang Y, Chen Y, Teng J, Fang C, Chen S, Jia M, Liu Z, Kang S, Chen Y, Li G, Niu Y, Cai Q.
Yang S, et al. Among authors: teng j.
Heliyon. 2024 Apr 4;10(7):e29215. doi: 10.1016/j.heliyon.2024.e29215. eCollection 2024 Apr 15.
Heliyon. 2024.
PMID: 38623200
Free PMC article.
Review.